Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized, placebo-controlled study of sorafenib in advanced hepatocellular carcinoma
2004-001773-26Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Primary efficacy variables. Started Feb 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2004-001773-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001773-26.